Pharmaceuticals, Biotechnology and Life Sciences
Prommune has completed completion of its third proof of concept study in pigs for its lead products HeptaVac, a self-adjuvating peptide vaccine cocktail and HISP-P, an immunoactivator and molecular adjuvant both for use in pigs with Swine Influenza A Virus infections.
Otsuka Pharmaceutical and Mylan N.V. have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries.
Karo Pharma will launch voluntary cash offer to acquire the entire issued share capital of Weifa for € 3.78 per share in cash.
European Commission (EC) approved Novartis’s Kisqali (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer as initial endocrine-based therapy.
Molecular Health, a pioneer in data and analytics-driven precision medicine from Heidelberg, Germany, seeks to expand its efforts to establish…
On Tuesday, the American Society for Parenteral and Enteral Nutrition (ASPEN), and Baxter International, a global leader in nutrition therapy, announced “SmartPN,” a comprehensive collaboration providing healthcare professionals with educational tools on the appropriate use of parenteral nutrition (PN) therapy.
OptiBiotix Health, has entered into an agreement for the manufacturing and supply agreement with Sacco for the USA and the…
Quantum Pharma posted financial results for the first half 2017 with revenue increased by 13% to £36.2M mostly from growth from the Niche Pharmaceuticals division.
When women are pregnant they take care to eat right and refrain from smoking and drinking alcoholic beverages. But what…
AstraZeneca’s and Merck’s Lynparza new tablet’s formulation has been approved as maintenance treatment for women with platinum-sensitive recurrent ovarian cancer regardless of BRCA-mutation status, the companies said Friday.